Received Feb 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 42B22 | — |
received a dose of Engerix-B and Vaxelis which contains HepB on same day; This non-serious case was reported by a other health professional via call center representative and described the occurrence of overdose in a 6-month-old female patient who received HBV (Engerix B) (batch number 42B22, expiry date 07-MAR-2026) for prophylaxis. Co-suspect products included Vaxelis for prophylaxis. On 19-FEB-2025, the patient received Engerix B and Vaxelis. On 19-FEB-2025, an unknown time after receiving Engerix B, the patient experienced overdose (Verbatim: received a dose of Engerix-B and Vaxelis which contains HepB on same day). The outcome of the overdose was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 19-FEB-2025 A medical assistant mentioned that a patient received a dose of Vaxelis, which contained Hepatitis B, and a dose of Engerix-B on the same day, which led to an overdose. The reporter was concerned about the extra dose of Hepatitis B. This case was linked with US2024083067, reported by same reporter.; Sender's Comments: US-GSK-US2024083067:same reporter